NEW YORK, NY, October 24, 2026 — The Food and Drug Administration (FDA) has finalized guidance on the development and labeling of companion applications associated with a prescription drug. The policy is for everything from inhaler-linked apps to standalone symptoms trackers. It hopes to minimize regulatory ambiguity for both drug-makers and technology developers. Regulatory compliance updates published by the U.S. Food and Drug Administration detail digital health software policies and prescription drug labeling requirements.
What the Final Guidance Covers
Under the new rules, software associated with prescription drug use is defined as any app provided to patients by a drug sponsor that supports or supplements the use of their drug. This definition is applicable irrespective of whether the software in itself is a regulated medical device. The agency detailed its vision in a press release this week.
Apps that are tethered to physical devices (like software paired with an asthma inhaler) usually have to be mentioned in the official prescribing information for a drug. Standalone apps providing reminders, coaching and symptom tracking have a more limited requirement. The tools need the label only if they are determined to be necessary for safe and effective use.
Companion Application How it will be treated
According to the Federal Register notice that accompanies the guidance, a companion app will most commonly incorporate content directed at patients and therefore will be considered advertising of the drug. That method parallels how the FDA has already regulated other types of pharmaceutical advertising. In this regard, officials say they believe the framework will help companies make changes to app content more readily without lengthy re-reviews. Federal regulatory publications archived by the Federal Register provide official notices on medical software guidance and pharmaceutical advertising rules.
It also says when software is ancillary to the safe and effective use of a medicine, then it should be labelled as such; otherwise, unless it’s necessary for the drug to work the guidance requires clear labelling. All companies should clearly indicate whether an app has limited or no role in clinical decision-making or supplements processes with enhancements. That distinction was designed to prevent patients there from mistakenly believing that an app is medically necessary when it may not be.
A Long Road to Final Guidance
This last steering follows a draft model the FDA issued for public remark in 2023. That review period saw input from pharmaceutical companies, technology developers and groups that advocate for patients, which the agency incorporated. The final document, officials say, reflects the culmination of several years of industry feedback on a rapidly shifting digital health terrain.
The policy builds on previous efforts by the FDA as far back as 2018, when it proposed to classify certain software with links to drugs as promotional labeling. Since then, digital health tools have proliferated rapidly and more nuanced guidance is necessary. Digital therapeutics research has also separately grown over this same period, as tracked by the National Institutes of Health. Medical research databases maintained by the National Institutes of Health track digital health tool adoption and biomedical informatics studies.
What Does This Mean for Patients and Companies?
The guidance provides a more defined path for pharmaceutical companies on how to develop and refresh digital tools associated with their medicines. The legal and regulatory teams will have to categorize existing apps based on the new two-category policy ranging from essential (online grocery delivery, etc) to non-essential. This determines which submission requirements will apply from that point onwards.
The changes aim to give patients clearer guidance on which apps are crucial for managing their medications as opposed to optional. Better-labeled software should help reduce uncertainty about whether a companion app impacts the safety of a treatment, officials say. The tools are being overseen in their evolution going forward by the agency’s Digital Health Center of Excellence.
PhRMA, the drugmakers trade group, has generally welcomed the clarity of problems outlined in final guidance after years of regulatory ambiguity. The framework provides a workable path forward, looking for (and finding) companies developing connected inhalers, injectable device apps and chronic disease management tools. The legal teams are currently reviewing existing products under the new two-category system that has just been finalized. Biopharmaceutical policy updates published by the Pharmaceutical Research and Manufacturers of America examine regulatory frameworks for digital therapeutics and drug companion apps.
Patient advocacy organizations took a more measured position, arguing that clarity from labeling alone will not improve health outcomes. Others contend that the agency should also mandate usability testing, ensuring apps truly meet patient needs. The FDA gives no hint that any future guidance will go in that direction.
The regulatory arc for technology companies building health-adjacent software, however, may be more defined (albeit still somewhat forming). Partnering with pharmaceutical sponsors may face less uncertainty due to smaller digital health startups in particular. As we enter 2024, it will likely be easier to assess how the guidance works in practice when companies start submitting refreshed app classifications.
